Source:http://linkedlifedata.com/resource/pubmed/id/10785238
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2000-6-20
|
pubmed:abstractText |
OBJECTIVE: To study whether minimal interference in the process of selection of the single dominant follicle may serve as the basis for a simplified ovarian stimulation regimen for IVF. DESIGN: Single-center randomized pilot study. SETTING: Tertiary referral fertility center. PATIENT(s): Fifteen normo-ovulatory patients with a regular indication for IVF. INTERVENTION(s): Ovarian stimulation for IVF was begun with 100 or 150 IU/d recombinant FSH starting on cycle day 5. From cycle day 8 or later, cotreatment was begun with 0.25 mg/d GnRH antagonist. No luteal support was provided. MAIN OUTCOME MEASURE(s): Total number of dominant follicles and characteristics of the endocrine cycle. RESULT(s): Multiple follicle development occurred in five of eight patients in the 100-IU group and in all seven women in the 150-IU group. Follicular phase and luteal phase lengths were normal, but the endocrine profile was abnormal. CONCLUSION(s): A fixed daily dose of 150 IU recombinant FSH starting in the midfollicular phase resulted in ongoing growth of a restricted number of dominant follicles and sufficient oocytes retrieved to lead to ET. A marked reduction in the total amount of gonadotropins administered compared with standard treatment was achieved. Withholding luteal support did not exclude pregnancies.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Follicle Stimulating Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Hormone Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/cetrorelix
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0015-0282
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
73
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1051-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10785238-Adult,
pubmed-meshheading:10785238-Drug Therapy, Combination,
pubmed-meshheading:10785238-Estradiol,
pubmed-meshheading:10785238-Female,
pubmed-meshheading:10785238-Fertilization in Vitro,
pubmed-meshheading:10785238-Follicle Stimulating Hormone,
pubmed-meshheading:10785238-Follicular Phase,
pubmed-meshheading:10785238-Gonadotropin-Releasing Hormone,
pubmed-meshheading:10785238-Hormone Antagonists,
pubmed-meshheading:10785238-Humans,
pubmed-meshheading:10785238-Luteal Phase,
pubmed-meshheading:10785238-Luteinizing Hormone,
pubmed-meshheading:10785238-Ovulation Induction,
pubmed-meshheading:10785238-Pilot Projects,
pubmed-meshheading:10785238-Pregnancy Rate,
pubmed-meshheading:10785238-Progesterone,
pubmed-meshheading:10785238-Recombinant Proteins
|
pubmed:year |
2000
|
pubmed:articleTitle |
A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.
|
pubmed:affiliation |
Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|